ArticleFrontiers in immunology2021
PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06500715 (Acupuncture as add-on to GCS-F Treatment for Reducing Febrile Neutropenia-related Hospitalization in Patients Undergoing Doxorubicin-based Treatment for Sarcoma), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acupuncture as add-on to GCS-F Treatment for Reducing Febrile Neutropenia-related Hospitalization in Patients Undergoing Doxorubicin-based Treatment for Sarcoma: a Randomized Crossover Study
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Electroacupuncture Alleviates Chemotherapy-Induced Peripheral Neuropathy via Multi-target Modulation: A Review from Mechanisms to Intervention.Chinese journal of integrative medicine · 2026Review
- Acupuncture for post-chemoradiotherapy complications in lung cancer with bone metastasis: a case report and literature review.Frontiers in oncology · 2026Article
- Acupuncture in remodeling the tumor microenvironment: current status and challenges.Frontiers in immunology · 2026Review
- Vagal stimulation ameliorates murine colitis by regulating SUMOylation.Science translational medicine · 2024Article
- [Complete remission of a migraine after treatment with cisplatin].Revista de neurologia · 2023Article
- Mechanism of traditional Chinese medicine in treating overactive bladder.International urology and nephrology · 2023Review
- Shared nociceptive dorsal root ganglion neurons participating in acupoint sensitization.Frontiers in molecular neuroscience · 2022Article
- Clinical Efficacy and Potential Mechanisms of Acupoint Stimulation Combined With Chemotherapy in Combating Cancer: A Review and Prospects.Frontiers in oncology · 2022Review
- Research Progress on Improving the Efficiency of CDT by Exacerbating Tumor Acidification.International journal of nanomedicine · 2022Review
- Moxibustion Promotes Tumor Immune Responses and Vascular Normalization to Enhance Antitumor Effect of Cisplatin in Lewis Lung Carcinoma Mice.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
Platinum-based chemotherapy is an effective treatment used in multiple tumor treatments, but produces severe side effects including neurotoxicity, anemia, and immunosuppression, which limits its anti-tumor efficacy and increases the risk of infections. Electroacupuncture (EA) is often used to ameliorate these side effects, but its mechanism is unknown. Here, we report that EA on ST36 and SP6 prevents cisplatin-induced neurotoxicity and immunosuppression. EA induces neuroprotection, prevents pain-related neurotoxicity, preserves bone marrow (BM) hematopoiesis, and peripheral levels of leukocytes. EA activates sympathetic BM terminals to release pituitary adenylate cyclase activating polypeptide (PACAP). PACAP-receptor PAC1-antagonists abrogate the effects of EA, whereas PAC1-agonists mimic EA, prevent neurotoxicity, immunosuppression, and preserve BM hematopoiesis during cisplatin chemotherapy. Our results indicate that PAC1-agonists may provide therapeutic advantages during chemotherapy to treat patients with advanced neurotoxicity or neuropathies limiting EA efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.